We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Awarded Grant to Accelerate Drug Discovery
News

Galapagos Awarded Grant to Accelerate Drug Discovery

Galapagos Awarded Grant to Accelerate Drug Discovery
News

Galapagos Awarded Grant to Accelerate Drug Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Awarded Grant to Accelerate Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that it has been awarded a €837,000 grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). Galapagos will elucidate the structure of novel drug targets and related small molecules in its bone & joint disease portfolio.

The two-year project "Drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors" focuses on Galapagos' novel drug targets and the candidate drugs that bind to these targets. This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the renowned Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).

"This grant gives us an opportunity to collaborate with the VIB's top structural biology group, thereby adding to our drug discovery capabilities," said Graham Dixon, SVP Drug Discovery for Galapagos.

"Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone & joint diseases."
Advertisement